Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque

Heather L. Teague; Milena Aksentijevich; Elena Stansky; Joanna I. Silverman; Nevin J. Varghese; Amit K. Dey; Youssef Elnabawi; Aditya Goyal; Pradeep K. Dagur; Marcus Y. Chen; J. Philip McCoy; Martin P. Playford; Christopher Hourigan; Joel M. Gelfand; Nehal N. Mehta

doi:10.1016/j.jid.2019.07.724

Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque

Heather L. Teague, Milena Aksentijevich, Elena Stansky, Joanna I. Silverman, Nevin J. Varghese, Amit K. Dey, Youssef Elnabawi, Aditya Goyal, Pradeep K. Dagur, Marcus Y. Chen, J. Philip McCoy, Martin P. Playford, Christopher Hourigan, Joel M. Gelfand, Nehal N. Mehta

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	912-915.e1
Journal	Journal of Investigative Dermatology
Volume	140
Issue number	4
DOIs	https://doi.org/10.1016/j.jid.2019.07.724
State	Published - Apr 2020
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Dermatology
Cell Biology

Access to Document

10.1016/j.jid.2019.07.724

Cite this

Teague, H. L., Aksentijevich, M., Stansky, E., Silverman, J. I., Varghese, N. J., Dey, A. K., Elnabawi, Y., Goyal, A., Dagur, P. K., Chen, M. Y., McCoy, J. P., Playford, M. P., Hourigan, C., Gelfand, J. M., & Mehta, N. N. (2020). Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque. Journal of Investigative Dermatology, 140(4), 912-915.e1. https://doi.org/10.1016/j.jid.2019.07.724

Teague, HL, Aksentijevich, M, Stansky, E, Silverman, JI, Varghese, NJ, Dey, AK, Elnabawi, Y, Goyal, A, Dagur, PK, Chen, MY, McCoy, JP, Playford, MP, Hourigan, C, Gelfand, JM & Mehta, NN 2020, 'Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque', Journal of Investigative Dermatology, vol. 140, no. 4, pp. 912-915.e1. https://doi.org/10.1016/j.jid.2019.07.724

@article{4b5e3cc39ce2438686113c212f94e5cc,

title = "Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque",

author = "Teague, {Heather L.} and Milena Aksentijevich and Elena Stansky and Silverman, {Joanna I.} and Varghese, {Nevin J.} and Dey, {Amit K.} and Youssef Elnabawi and Aditya Goyal and Dagur, {Pradeep K.} and Chen, {Marcus Y.} and McCoy, {J. Philip} and Playford, {Martin P.} and Christopher Hourigan and Gelfand, {Joel M.} and Mehta, {Nehal N.}",

note = "Funding Information: The authors would like to thank the NIH Clinical Center outpatient clinic-7 clinical care team for the excellent care they provide our participants. This study was supported by the National Heart, Lung and Blood Institute Intramural Research Program (HL006193- 05). This research was also made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH, and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation (DDCF Grant #2014194), the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, Elsevier, and other private donors. Funding Information: The authors would like to thank the NIH Clinical Center outpatient clinic-7 clinical care team for the excellent care they provide our participants. This study was supported by the National Heart, Lung and Blood Institute Intramural Research Program ( HL006193- 05 ). This research was also made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH , and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation (DDCF Grant #2014194), the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, Elsevier, and other private donors. Funding Information: Dr. Mehta is a full-time US government employee and has served as a consultant for Amgen, Eli Lilly, and Leo Pharma receiving grants/other payments; as a principal investigator and/or investigator for AbbVie, Celgene, Janssen Pharmaceuticals, Inc, and Novartis receiving grants and/or research funding; and as a principal investigator for the National Institute of Health receiving grants and/or research funding. Dr. Gelfand served as a consultant for BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Boehringer Ingelheim, Janssen, Novartis Corp , Celgene, Ortho Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics, and Novartis. Dr. Gelfand is a copatent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr. Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology. All other authors declare no conflicts of interests in relation to the work presented in this manuscript. ",

year = "2020",

month = apr,

doi = "10.1016/j.jid.2019.07.724",

language = "English (US)",

volume = "140",

pages = "912--915.e1",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque

AU - Teague, Heather L.

AU - Aksentijevich, Milena

AU - Stansky, Elena

AU - Silverman, Joanna I.

AU - Varghese, Nevin J.

AU - Dey, Amit K.

AU - Elnabawi, Youssef

AU - Goyal, Aditya

AU - Dagur, Pradeep K.

AU - Chen, Marcus Y.

AU - McCoy, J. Philip

AU - Playford, Martin P.

AU - Hourigan, Christopher

AU - Gelfand, Joel M.

AU - Mehta, Nehal N.

N1 - Funding Information: The authors would like to thank the NIH Clinical Center outpatient clinic-7 clinical care team for the excellent care they provide our participants. This study was supported by the National Heart, Lung and Blood Institute Intramural Research Program (HL006193- 05). This research was also made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH, and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation (DDCF Grant #2014194), the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, Elsevier, and other private donors. Funding Information: The authors would like to thank the NIH Clinical Center outpatient clinic-7 clinical care team for the excellent care they provide our participants. This study was supported by the National Heart, Lung and Blood Institute Intramural Research Program ( HL006193- 05 ). This research was also made possible through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH , and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation (DDCF Grant #2014194), the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, Elsevier, and other private donors. Funding Information: Dr. Mehta is a full-time US government employee and has served as a consultant for Amgen, Eli Lilly, and Leo Pharma receiving grants/other payments; as a principal investigator and/or investigator for AbbVie, Celgene, Janssen Pharmaceuticals, Inc, and Novartis receiving grants and/or research funding; and as a principal investigator for the National Institute of Health receiving grants and/or research funding. Dr. Gelfand served as a consultant for BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Boehringer Ingelheim, Janssen, Novartis Corp , Celgene, Ortho Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics, and Novartis. Dr. Gelfand is a copatent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr. Gelfand is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology. All other authors declare no conflicts of interests in relation to the work presented in this manuscript.

PY - 2020/4

Y1 - 2020/4

UR - http://www.scopus.com/inward/record.url?scp=85075478936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075478936&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2019.07.724

DO - 10.1016/j.jid.2019.07.724

M3 - Article

C2 - 31539534

AN - SCOPUS:85075478936

SN - 0022-202X

VL - 140

SP - 912-915.e1

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 4

ER -

Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this